ATE389668T1 - Tumorantigen - Google Patents

Tumorantigen

Info

Publication number
ATE389668T1
ATE389668T1 AT01984425T AT01984425T ATE389668T1 AT E389668 T1 ATE389668 T1 AT E389668T1 AT 01984425 T AT01984425 T AT 01984425T AT 01984425 T AT01984425 T AT 01984425T AT E389668 T1 ATE389668 T1 AT E389668T1
Authority
AT
Austria
Prior art keywords
peptide
tumor antigen
polynucleotide
tumor antigens
tumor
Prior art date
Application number
AT01984425T
Other languages
English (en)
Inventor
Kyogo Itoh
Original Assignee
Greenpeptide Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenpeptide Co Ltd filed Critical Greenpeptide Co Ltd
Application granted granted Critical
Publication of ATE389668T1 publication Critical patent/ATE389668T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01984425T 2000-07-31 2001-07-30 Tumorantigen ATE389668T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000231814 2000-07-31

Publications (1)

Publication Number Publication Date
ATE389668T1 true ATE389668T1 (de) 2008-04-15

Family

ID=18724591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984425T ATE389668T1 (de) 2000-07-31 2001-07-30 Tumorantigen

Country Status (9)

Country Link
US (6) US7148326B2 (de)
EP (1) EP1306431B1 (de)
JP (1) JP4900884B2 (de)
AT (1) ATE389668T1 (de)
AU (1) AU2002227498A1 (de)
CA (1) CA2417570C (de)
DE (1) DE60133287T2 (de)
ES (1) ES2304398T3 (de)
WO (1) WO2002010369A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025569A1 (en) * 2001-09-18 2003-03-27 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
US20080200088A1 (en) * 2007-02-21 2008-08-21 Chong Pyung An Method for reducing interference fringes in a display device
CA2697896C (en) 2007-09-18 2016-06-28 Green Peptide Co., Ltd. Ctl inducer composition
EP2123748A1 (de) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-Oligoadenylat-Synthetase 3 zur Vorbeugung und Behandlung von positivgerichteten einsträngigen RNA-Virusinfektionen
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
KR20120081972A (ko) 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
WO2011108628A1 (ja) * 2010-03-03 2011-09-09 東レ株式会社 胃癌検出用マーカー及び胃癌検出方法
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
CN103765220B (zh) * 2011-08-29 2016-02-17 东丽株式会社 大肠癌或食道癌的检测用标志物和检查方法
CA2873155C (en) * 2012-09-11 2022-07-26 Oncotherapy Science, Inc. Ube2t peptides and vaccines containing the same
EP4282419A1 (de) 2012-12-20 2023-11-29 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
WO2014136814A1 (ja) 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
PT3061771T (pt) 2013-10-21 2020-05-06 Taiho Pharmaceutical Co Ltd Novo péptido unido a quatro epitopos ctl
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3647433B1 (de) * 2017-06-30 2023-04-12 Osaka University Verfahren zur vorhersage der wirkung einer tumorimmunotherapie unter verwendung von tumorzytotoxischer aktivität von peripheren t-zellen im blut als index
KR102666724B1 (ko) 2017-10-26 2024-05-20 오츠카 세이야쿠 가부시키가이샤 이노시톨인산 함유 조성물
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
TWI805792B (zh) 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
US20230055953A1 (en) 2019-12-26 2023-02-23 Taiho Pharmaceutical Co., Ltd. Agent for adjuvant therapy
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2000189168A (ja) * 1998-12-28 2000-07-11 Hiroshi Handa 新規転写伸長抑制因子
AU6321400A (en) * 1999-08-17 2001-03-13 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins

Also Published As

Publication number Publication date
US20070031431A1 (en) 2007-02-08
JP4900884B2 (ja) 2012-03-21
US20070031433A1 (en) 2007-02-08
US7148326B2 (en) 2006-12-12
EP1306431A1 (de) 2003-05-02
DE60133287T2 (de) 2009-03-26
US7404270B2 (en) 2008-07-29
DE60133287D1 (de) 2008-04-30
AU2002227498A1 (en) 2002-02-13
WO2002010369A1 (en) 2002-02-07
US20070071767A1 (en) 2007-03-29
US7427660B2 (en) 2008-09-23
US7524930B2 (en) 2009-04-28
US7408037B2 (en) 2008-08-05
CA2417570C (en) 2010-12-07
CA2417570A1 (en) 2003-01-31
US20030175288A1 (en) 2003-09-18
US20070031432A1 (en) 2007-02-08
US20070066804A1 (en) 2007-03-22
US7432354B2 (en) 2008-10-07
EP1306431A4 (de) 2004-08-18
ES2304398T3 (es) 2008-10-16
EP1306431B1 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
ATE389668T1 (de) Tumorantigen
CY1105597T1 (el) Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1
DK2316940T3 (da) Fokuserede biblioteker af genpakker
FI950665A0 (fi) Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita
EP1731605A4 (de) Aus wt1 stammende krebsantigenpeptide
DE69910580D1 (de) Von der telomerase abgeleitete antigene peptide
AU5810201A (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
ATE464383T1 (de) Tumor antigen
DK1370284T3 (da) Bakteriofag-medieret immunisering
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
ATE451461T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO1999057277A3 (en) Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO2003008450A1 (en) Tumor antigen
WO1999063093A3 (en) Basb027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
ATE397069T1 (de) Basb205 polypeptide und dafür kodierende polynukleotide
DE60140006D1 (de) Polypeptide aus haemophilus influenza
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
ATE293693T1 (de) Moraxella catarrhalis antigen basb117
DE60019613D1 (de) Moraxella catarrhalis antigen basb120
ATE311458T1 (de) Basb111 polypeptid und polynukleotid aus moraxella catharralis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties